Table 1 Characteristics of the cohort

Age

Median, years

54.0

53.0

54.0

Range, years

29 to 82

42 to 67

29 to 82

No data

14/69

1/10

15/79

Lesion size

Median, mm

32.0

40.0

32.8

Range, mm

5 to 145

11 to 103

5 to 145

Nuclear grade

High

35/72 (48.6%)

4/10 (40%)

39/82 (47.6%)

Intermediate

31/72 (43.1%)

6/10 (60%)

37/82 (45.1%)

Low

6/72 (8.3%)

0/10 (0%)

6/82 (7.3%)

Predominant architectural pattern

Solid

37/72 (51.4%)

10/10 (100%)

47/82 (57.3%)

Cribriform

17/72 (23.6%)

0/10 (0%)

17/82 (20.7%)

Micropapillary

11/72 (15.3%)

0/10 (0%)

11/82 (13.4%)

Clinging

4/72 (5.6%)

0/10 (0%)

4/82 (4.9%)

Cancerisation of lobules

2/72 (2.8%)

0/10 (0%)

2/82 (2.4%)

Papillary

1/72 (1.4%)

0/10 (0%)

1/82 (1.2%)

Comedo necrosis

Present

29/72 (40.3%)

6/10 (60%)

35/82 (42.7%)

Absent

43/72 (59.7%)

4/10 (40%)

47/82 (57.3%)

Estrogen receptor status

Positive

48/67 (71.6%)

7/8 (87.5%)

55/75 (73.3%)

Negative

19/67 (28.4%)

1/8 (12.5%)

20/75 (26.7%)

No data

5/72

2/10

7/82

Progesterone receptor status

Positive

40/67 (59.7%)

3/8 (37.5%)

43/75 (57.3%)

Negative

27/67 (40.3%)

5/8 (62.5%)

32/75 (42.7%)

No data

5/72

2/10

7/82

HER2 amplification

Amplified

20/67 (29.9%)

2/8 (25%)

22/75 (29.3%)

Non-amplified

47/67 (70.1%)

6/8 (75%)

53/75 (70.7%)

No data

5/72

2/10

7/82

Intrinsic subtype

Luminal

38/67 (56.7%)

6/8 (75%)

44/75 (58.7%)

HER2

20/67 (29.9%)

2/8 (25%)

22/75 (29.3%)

Basal

2/67 (3.0%)

0/8 (0%)

2/75 (2.6%)

Negative

7/67 (10.4%)

0/8 (0%)

7/75 (9.3%)

No data

5/72

2/10

7/82